[HTML][HTML] Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: a systematic review and network meta-analysis
J Jiang, Y Li, Q Jiang, Y Jiang, H Qin, Y Li - Journal of Infection, 2024 - Elsevier
Objectives This study aimed to determine the association of early use of oral antiviral drugs
(including nirmatrelvir-ritonavir and molnupiravir) with the risk of PCC and compare the …
(including nirmatrelvir-ritonavir and molnupiravir) with the risk of PCC and compare the …
Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID-19 in patients with cirrhosis
Objectives This retrospective cohort study assessed the clinical effectiveness of
nirmatrelvirplus ritonavir (NMV-r) in treating COVID-19 in patients with liver cirrhosis (LC) …
nirmatrelvirplus ritonavir (NMV-r) in treating COVID-19 in patients with liver cirrhosis (LC) …
Efficacy of nirmatrelvir and ritonavir for post‐acute COVID‐19 sequelae beyond 3 months of SARS‐CoV‐2 infection
The effect of nirmatrelvir plus ritonavir (NMV‐r) on post‐acute COVID‐19 sequelae beyond 3
months of SARS‐CoV‐2 infection remains unknown. This retrospective cohort study utilized …
months of SARS‐CoV‐2 infection remains unknown. This retrospective cohort study utilized …
Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID‐19
The aim of this study was to investigate the clinical efficacy of a combination of nirmatrelvir
and ritonavir (NMV‐r) for treating COVID‐19 in patients with diabetes mellitus (DM). This …
and ritonavir (NMV‐r) for treating COVID‐19 in patients with diabetes mellitus (DM). This …
Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19
Objective To investigate the association between nirmatrelvir plus ritonavir (NMV-r) and the
outcomes of non-hospitalized obese patients with coronavirus disease 2019 (COVID-19) …
outcomes of non-hospitalized obese patients with coronavirus disease 2019 (COVID-19) …
Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID‐19 and substance use disorders based on real‐world data
This study assessed the clinical efficacy of nirmatrelvir plus ritonavir (NMV‐r) in treating
patients with coronavirus disease‐2019 (COVID‐19) and substance use disorders (SUDs) …
patients with coronavirus disease‐2019 (COVID‐19) and substance use disorders (SUDs) …
Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors
We read with interest the retrospective observational study investigating the short-term effect
of oral anti-viral agents on United States Veterans aged 65 years and older who were at …
of oral anti-viral agents on United States Veterans aged 65 years and older who were at …
[HTML][HTML] Omega-3 polyunsaturated fatty acids and the psychiatric post-acute sequelae of COVID-19: A one-year retrospective cohort analysis of 33,908 patients
Background Early prevention and management of psychiatric symptoms in long COVID (or
post-COVID-19 conditions) are crucial for reducing long-term disability. Existing clinical …
post-COVID-19 conditions) are crucial for reducing long-term disability. Existing clinical …
Effectiveness of oral antiviral agents on long‐term cardiovascular risk in nonhospitalized patients with COVID‐19: A multicenter matched cohort study
Although a novel oral antiviral agent can improve short‐term COVID‐19 outcomes, its effects
on the long‐term outcomes, namely the risk of major adverse cardiovascular events …
on the long‐term outcomes, namely the risk of major adverse cardiovascular events …
[HTML][HTML] Comparison of post-acute sequelae following hospitalization for COVID-19 and influenza
Background Few studies have directly compared the risk and magnitude of post-acute
sequelae following COVID-19 and influenza, and most of these studies were conducted …
sequelae following COVID-19 and influenza, and most of these studies were conducted …